Janssen Forms Global Public Health Group To Deliver Its Medicines To Developing World
This article was originally published in PharmAsia News
Executive Summary
With the formation of the GPH group, Janssen joins GSK and Sanofi in putting corporate focus on developing and delivering affordable medicines for developing countries. But where GSK seeks to improve outcomes and turn a profit, for now Janssen’s first priority is human health.
You may also be interested in...
Corporate Responsibility With Teeth: GSK’s Developing Countries Unit
Initiative to build health care infrastructure and create a sales channel for GSK medicines is starting to yield tangible results.
J&J’s Sirturo Approval Tied To Expansive Post-Marketing Study Program
The first drug approved for multi-drug resistant tuberculosis, Sirturo obtained accelerated approval based on data from two Phase II studies, but has a troubling safety database, including 10 deaths in the treatment arm of its Phase II program.
ImmunoGen’s Elahere Data In Avastin-Naïve Ovarian Cancer Prompt Discussion About Earlier Use
The presenter on the MIRASOL study called the data “practice changing,” while the discussant cited Sutro’s STRO-002 as a potential option for patients with low folate receptor alpha expression.